ArticleBMC infectious diseases2026
Health-related quality of life in IBD patients with long COVID under China's normalized COVID-19 management.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionAlthough the COVID pandemic has gradually subsided, many patients have experienced complicated long-term symptoms, collectively known as "long-COVID", which is commonly associated with persistent discomfort and decrease in quality of life. Individuals with immune-mediated inflammatory diseases, such as inflammatory bowel disease (IBD), are particularly vulnerable in the context of COVID infection, while the influence from "long-COVID" remains unrevealed. This cross-sectional study aims to assess health-related quality of life (HRQoL) among IBD patients with long COVID and to identify factors associated with HRQoL impairment.
methodsA cross-sectional survey was conducted from September 16 to October 10, 2023, among 235 IBD patients who had been treated at Nanjing BenQ Medical Center and Nanjing Jinling Hospital. The survey collected demographic data, COVID-19-related information, and HRQoL assessments using the Short Inflammatory Bowel Disease Questionnaire (SIBDQ). Statistical analyses, including Chi-square tests, non-parametric tests, and multivariate linear regression, were employed to identify factors associated with long COVID and HRQoL.
resultsAmong 235 participants, 221 (94.04%) reported COVID-19 infection and 15 of 221 (6.79%) met the study definition of long COVID. Vaccination status differed by long-COVID status in an exploratory unadjusted comparison (p = 0.033); this finding was based on only 15 cases and was not adjusted for confounding. Participants with long COVID had a lower median SIBDQ score than those without long COVID (43.00 vs. 53.00; p = 0.009). In the multivariable model, any post-COVID-19 symptoms and symptom duration were entered as nested indicators. A duration of ≥ 4 weeks was associated with an additional 8.52-point lower SIBDQ score beyond the association of any post-COVID-19 symptoms (B=-8.52; 95% CI, -13.85 to -3.18; p = 0.002).
conclusionParticipants meeting the study definition of long COVID reported lower HRQoL than those without long COVID. However, because validated IBD activity measures were not collected, the observed difference cannot be separated from the possible effect of underlying IBD activity. The vaccination finding is exploratory. Larger prospective studies with standardized disease-activity assessment are required to confirm these associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.